Heartland Financial USA Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $8.28 billion. The enterprise value is $8.56 billion.
Important Dates
The last earnings date was Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | Aug 18, 2025 |
Share Statistics
Bio-Techne has 156.77 million shares outstanding. The number of shares has decreased by -0.66% in one year.
| Current Share Class | 156.77M |
| Shares Outstanding | 156.77M |
| Shares Change (YoY) | -0.66% |
| Shares Change (QoQ) | -2.01% |
| Owned by Insiders (%) | 1.09% |
| Owned by Institutions (%) | 101.41% |
| Float | 154.91M |
Valuation Ratios
The trailing PE ratio is 114.85 and the forward PE ratio is 26.30. Bio-Techne's PEG ratio is 2.69.
| PE Ratio | 114.85 |
| Forward PE | 26.30 |
| PS Ratio | 6.82 |
| Forward PS | 6.22 |
| PB Ratio | 4.27 |
| P/TBV Ratio | 14.47 |
| P/FCF Ratio | 32.28 |
| P/OCF Ratio | 28.80 |
| PEG Ratio | 2.69 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 36.75, with an EV/FCF ratio of 33.38.
| EV / Earnings | 116.67 |
| EV / Sales | 7.02 |
| EV / EBITDA | 36.75 |
| EV / EBIT | 69.57 |
| EV / FCF | 33.38 |
Financial Position
The company has a current ratio of 3.46, with a Debt / Equity ratio of 0.23.
| Current Ratio | 3.46 |
| Quick Ratio | 2.10 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 1.74 |
| Debt / FCF | 1.73 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 3.68% and return on invested capital (ROIC) is 3.17%.
| Return on Equity (ROE) | 3.68% |
| Return on Assets (ROA) | 2.92% |
| Return on Invested Capital (ROIC) | 3.17% |
| Return on Capital Employed (ROCE) | 5.17% |
| Revenue Per Employee | $399,880 |
| Profits Per Employee | $24,066 |
| Employee Count | 3,050 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 2.21 |
Taxes
In the past 12 months, Bio-Techne has paid $25.06 million in taxes.
| Income Tax | 25.06M |
| Effective Tax Rate | 25.45% |
Stock Price Statistics
The stock price has decreased by -26.39% in the last 52 weeks. The beta is 1.39, so Bio-Techne's price volatility has been higher than the market average.
| Beta (5Y) | 1.39 |
| 52-Week Price Change | -26.39% |
| 50-Day Moving Average | 52.30 |
| 200-Day Moving Average | 61.58 |
| Relative Strength Index (RSI) | 49.06 |
| Average Volume (20 Days) | 2,500,122 |
Short Selling Information
The latest short interest is 6.34 million, so 4.04% of the outstanding shares have been sold short.
| Short Interest | 6.34M |
| Short Previous Month | 6.53M |
| Short % of Shares Out | 4.04% |
| Short % of Float | 4.09% |
| Short Ratio (days to cover) | 3.11 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.22 billion and earned $73.40 million in profits. Earnings per share was $0.46.
| Revenue | 1.22B |
| Gross Profit | 811.12M |
| Operating Income | 123.10M |
| Pretax Income | 232.35M |
| Net Income | 73.40M |
| EBITDA | 233.00M |
| EBIT | 123.10M |
| Earnings Per Share (EPS) | $0.46 |
Full Income StatementBalance Sheet
The company has $162.19 million in cash and $444.06 million in debt, giving a net cash position of -$281.87 million or -$1.80 per share.
| Cash & Cash Equivalents | 162.19M |
| Total Debt | 444.06M |
| Net Cash | -281.87M |
| Net Cash Per Share | -$1.80 |
| Equity (Book Value) | 1.92B |
| Book Value Per Share | 12.39 |
| Working Capital | 432.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $287.56 million and capital expenditures -$31.01 million, giving a free cash flow of $256.55 million.
| Operating Cash Flow | 287.56M |
| Capital Expenditures | -31.01M |
| Free Cash Flow | 256.55M |
| FCF Per Share | $1.64 |
Full Cash Flow StatementMargins
Gross margin is 66.50%, with operating and profit margins of 10.09% and 6.02%.
| Gross Margin | 66.50% |
| Operating Margin | 10.09% |
| Pretax Margin | 8.07% |
| Profit Margin | 6.02% |
| EBITDA Margin | 19.10% |
| EBIT Margin | 10.09% |
| FCF Margin | 21.03% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.61%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.61% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 69.57% |
| Buyback Yield | 0.66% |
| Shareholder Yield | 1.26% |
| Earnings Yield | 0.89% |
| FCF Yield | 3.10% |
Dividend DetailsAnalyst Forecast
The average price target for Bio-Techne is $69.82, which is 32.16% higher than the current price. The consensus rating is "Buy".
| Price Target | $69.82 |
| Price Target Difference | 32.16% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 10.28% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |
